Tell me about biomarkers that are relevant

There are several important biomarkers that are relevant for breast cancer diagnosis, treatment planning, and prognosis. According to the American Cancer Society, the three main biomarkers currently used in breast cancer care are:

1. Hormone Receptors (ER/PR): Estrogen receptor (ER) and progesterone receptor (PR) status indicates if the cancer's growth is supported by hormones. ER/PR+ cancers can be treated with hormone therapy. About 70-80% of breast cancers are ER/PR+.

2. HER2 Status: Human epidermal growth factor receptor 2 (HER2) is a protein that promotes cancer cell growth. HER2+ cancers can be treated with targeted drugs. About 10-20% of breast cancers are HER2+.

3. Ki-67: This protein is a marker of how fast cancer cells are growing and dividing. High Ki-67 levels are associated with more aggressive cancers. This marker helps determine prognosis and treatment approach.

The NCCN Guidelines for Breast Cancer also highlight some emerging biomarkers:

• PIK3CA gene mutations: May predict response to some targeted therapies
• PD-L1: An immune system biomarker that may indicate potential for immunotherapy
• Tumor mutational burden (TMB): High TMB may predict immunotherapy response

Multigene panel tests are also now used to analyze a range of genes to help refine prognosis and guide treatment decisions for some patients.

It's important to discuss the role of biomarker testing in your individual situation with your oncology team. Biomarker status, along with other factors like cancer stage and your overall health, help personalize treatment planning.